**Core Concept:**
In the context of renal failure, we need to consider the pharmacokinetic and pharmacodynamic changes that occur due to impaired kidney function. Renal failure leads to alterations in drug disposition, including reduced clearance, increased half-life, and accumulation of drugs. This can cause toxic effects and therapeutic failures.

**Why the Correct Answer is Right:**
The correct answer is **D.** Oral contraceptives (OCPs) are not typically used in renal failure due to their potential for causing severe complications. Oral contraceptives are primarily eliminated through the liver and to a lesser extent, through the kidneys. In renal failure, their clearance is reduced, leading to increased drug concentrations and potential toxic effects.

**Why Each Wrong Option is Incorrect:**

**Option A:** Glucose-lowering drugs, such as metformin, are often used in type 2 diabetes mellitus, but they are primarily eliminated through the liver, not the kidneys. Metformin does not significantly accumulate in renal failure, making it a safer choice compared to oral contraceptives.

**Option B:** Calcium channel blockers (CCBs) can be used in renal failure, as they primarily undergo renal excretion, but the reduced renal function does not significantly affect their elimination.

**Option C:** Sodium-glucose cotransporter-2 (SGLT2) inhibitors are used in type 2 diabetes mellitus but do not significantly accumulate in renal failure.

**Option D:** Oral contraceptives (OCPs) are not recommended in renal failure due to their potential for causing severe complications, as explained above.

**Clinical Pearl:**
When selecting medications for patients with renal impairment, it is crucial to consider not only the pharmacokinetic changes but also the specific medication-related risks and complications. A tailored approach with careful monitoring is essential for optimal patient care and safety in this patient population.